We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Electroporation Effective in Treating Hepatocellular Carcinoma

By HospiMedica International staff writers
Posted on 15 Dec 2010
A new technique called irreversible electroporation (IRE) holds promise for the treatment of hepatocellar carcinoma (HCC) and other soft tissue tumors.

Researchers at the University of Pisa (Italy) and other institutions participating in an ongoing European multicenter trial to study IRE have treated over 200 patients so far, and report promising results. More...
A planned phase 3 trial will enroll a further 25 patients with early-stage HCC at seven European centers; patients can have up to three tumors that are up to 3 cm in diameter each, and cannot be candidates for resection or transplantation. The primary endpoint is tumor response; secondary endpoints include safety, local recurrence, and overall survival.

Unlike radiofrequency ablation (RFA) or microwave techniques, IRE does not use thermal energy to kill tumor cells; instead, it uses electricity to break the cell membrane. The technique is cumbersome, requiring three electrodes and general anesthesia (GA) with muscle blockade, and uses a very high voltage (over 1,500 volts) to induce irreversible damage to cell membrane integrity, producing cell death. The placement of the needles is done under ultrasonography (US) or computed tomography (CT) imaging. Animal studies have shown that the area of ablation can be predicted precisely, thus preserving adjacent structures. The technique was presented at the 37th Annual VEITH Symposium, held during November 2010 in New York (NY, USA).

"This technique is promising. We have shown that tumors can be treated safety, and we can treat tumors that are in sites that are not ideal for RFA and microwave ablation,” said presenter Laura Crocetti, MD. "It is faster than RFA and microwave techniques, taking about 5 minutes for the entire procedure. The machine predicts the tumor volume and tells you the amount of voltage you need.”

The device under study is called the NanoKnife, a product of Angiodynamics (Latham, NY, USA), and is currently approved by the US Food and Drug Administration (FDA) for use in soft tissues alone. The NanoKnife uses direct current electrical fields to create nanoscale defects in the membranes of cells within a targeted soft tissue region; but although IRE effectively kills the tumors, it is unknown whether this translates to reduced recurrence or improved survival.

Related Links:
University of Pisa
Angiodynamics


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.